Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.88 USD | -10.28% | -18.18% | +24.14% |
Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
Mar. 19 | JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5 | MT |
Financials (USD)
Sales 2024 * | 39.05M | Sales 2025 * | 33.24M | Capitalization | 349M |
---|---|---|---|---|---|
Net income 2024 * | -83M | Net income 2025 * | -97M | EV / Sales 2024 * | 6.12 x |
Net cash position 2024 * | 110M | Net cash position 2025 * | 23.7M | EV / Sales 2025 * | 9.8 x |
P/E ratio 2024 * |
-4.34
x | P/E ratio 2025 * |
-3.99
x | Employees | 123 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.32% |
Latest transcript on Mersana Therapeutics, Inc.
1 day | -10.28% | ||
1 week | -18.18% | ||
Current month | -35.71% | ||
1 month | -38.72% | ||
3 months | -7.99% | ||
6 months | +117.36% | ||
Current year | +24.14% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Huber
CEO | Chief Executive Officer | 64 | 20-04-12 |
Director of Finance/CFO | 46 | 19-07-09 | |
David Mott
CHM | Chairman | 58 | 12-07-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | 16-07-31 |
David Mott
CHM | Chairman | 58 | 12-07-30 |
Anna Protopapas
BRD | Director/Board Member | 59 | 15-03-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.03% | 237 M€ | +1.49% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 2.88 | -10.28% | 3,535,445 |
24-04-23 | 3.21 | +1.90% | 1,880,124 |
24-04-22 | 3.15 | -3.08% | 1,803,183 |
24-04-19 | 3.25 | -2.69% | 2,390,380 |
24-04-18 | 3.34 | -5.11% | 1,273,917 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.14% | 349M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.02% | 22.2B | |
-16.53% | 21.23B | |
-8.49% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- MRSN Stock